TY - JOUR
T1 - Collagen XI Alpha 1 Chain, a Novel Therapeutic Target for Cancer Treatment
AU - Wu, Yi Hui
AU - Chou, Cheng Yang
N1 - Funding Information:
This work was supported by grants from the National Science Council (MOST: No. 108-2314-B-384-011-MY3, 108-2314-B-006-061-MY2 and 110-2314-B-006-036). The study was also supported by grants from the Chi Mei Medical Center, Liouying Campus (CLFHR10822, CLFHR10911, CMLMOST10901, CLFHR10921, CLFHR11015 and CMLMOST11101).
Publisher Copyright:
Copyright © 2022 Wu and Chou.
PY - 2022/6/29
Y1 - 2022/6/29
N2 - The extracellular matrix (ECM) plays an important role in the progression of cancer. Collagen is the most abundant component in ECM, and is involved in the biological formation of cancer. Although type XI collagen is a minor fibrillar collagen, collagen XI alpha 1 chain (COL11A1) expression has been found to be upregulated in a variety of human cancers including colorectal, esophagus, glioma, gastric, head and neck, lung, ovarian, pancreatic, salivary gland, and renal cancers. High levels of COL11A1 usually predict poor prognosis, owing to its association with angiogenesis, invasion, and drug resistance in cancer. However, little is known about the specific mechanism through which COL11A1 regulates tumor progression. Here, we have organized and summarized recent developments regarding the interactions between COL11A1 and intracellular signaling pathways and selected therapeutic agents targeting COL11A1, as these indicate its potential as a target for treatment of cancers, especially epithelial ovarian cancer.
AB - The extracellular matrix (ECM) plays an important role in the progression of cancer. Collagen is the most abundant component in ECM, and is involved in the biological formation of cancer. Although type XI collagen is a minor fibrillar collagen, collagen XI alpha 1 chain (COL11A1) expression has been found to be upregulated in a variety of human cancers including colorectal, esophagus, glioma, gastric, head and neck, lung, ovarian, pancreatic, salivary gland, and renal cancers. High levels of COL11A1 usually predict poor prognosis, owing to its association with angiogenesis, invasion, and drug resistance in cancer. However, little is known about the specific mechanism through which COL11A1 regulates tumor progression. Here, we have organized and summarized recent developments regarding the interactions between COL11A1 and intracellular signaling pathways and selected therapeutic agents targeting COL11A1, as these indicate its potential as a target for treatment of cancers, especially epithelial ovarian cancer.
UR - http://www.scopus.com/inward/record.url?scp=85134167466&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134167466&partnerID=8YFLogxK
U2 - 10.3389/fonc.2022.925165
DO - 10.3389/fonc.2022.925165
M3 - Review article
AN - SCOPUS:85134167466
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 925165
ER -
